Valeant Pharmaceuticals International has announced the formation of a new Patient Access and Pricing Committee that will be responsible for the pricing of the company’s drugs. The committee will be chaired initially by Joseph Papa, chairman and CEO of Valeant, and will include a multi-disciplinary team of Valeant employees, including doctors, scientists and other executives. Among other issues, the committee will review the pricing of Nitropress, Isuprel, Cuprimine and Syprine. The Valeant Board of Directors will oversee the Patient Access and Pricing Committee.
“Valeant has made mistakes in how it priced its drugs in the past, and we are committed to ensuring those mistakes are not repeated,” said Papa. “This new committee will take a disciplined approach to reviewing the company’s pricing of drugs, and will consider the impact on patients, doctors, and our healthcare industry partners. Valeant’s No. 1 priority is ensuring patients can access the medicines they need.”
